Abstract: A mixing and dispensing apparatus configured to be used in conjunction with a hydration backpack or similar liquid containments are disclosed. The apparatus comprises a reservoir containing a solvent positioned within the hydration backpack. The apparatus further comprises a housing with cartridges, which is in fluid communication with the reservoir via an inlet tube attached to one end of the housing. The cartridge configured to store a solute, which is in fluid communication with the housing via a mixing interface positioned on each cartridge. The opposing end of the housing is attached to an outlet tube, aiding in fluid communication with the housing. The cartridge is pressurized to allow the solute to be extruded through the mixing interface, thereby dissolving the solute with the solvent within the housing. A bite valve is distally positioned to the outlet tube, in which a user suctions the bite valve to allow the transfer of the dissolved solution to a user's mouth.

Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

Abstract: A system and method for configuring a microprocessor core may allow a microprocessor core to be configurable. Configuration may be dynamic or automatic using an application program. Microprocessor memory, decoding units, arithmetic logic units, register banks, storage, register bypass units, and a user interface may be configured. The configuration may also be used to optimize an instruction set to run on the microprocessor core.

Abstract: Methods for treating a plant comprise contacting a plant or a part of a plant with one or more of 9-oxononanoic acid, arachidonic acid, or a salt or ester thereof; wherein the amount is effective to increase tolerance to abiotic stress in the plant or to reduce a consequence of abiotic stress in the plant. Additional ingredients can be included such as dicarboxylic acids, pipecolic acid, or salicylic acid, or salts/esters thereof; sunblocks such as kaolin or calcium carbonate; carriers such as inert powders or liquids; and co-treatment materials such as fertilizers, plant nutrients, biostimulants, micronutrients, amino acids, plant hormones, pesticides, fungicides, insecticides, nematicide, stearic acid, vegetable oil, or phospholipid.

Abstract: A method for improving performance of a pipelined microprocessor by utilizing pipeline virtual registers allows for either decreased register spillage or decreased area and power consumption of a microprocessor. The microprocessor takes advantage of register bypass logic to write short-lived values to virtual registers, which are discarded instead of being written to the register bank, thus reducing register pressure by avoiding short-lived values being written to the register bank.

Abstract: The invention provides novel ligands of Kappa (?) opioid receptors, such as can be used to modulate a Kappa opioid receptor. Methods of synthesis and methods of use are also provided. Compounds of the invention can be used therapeutically in the treatment of dissociative disorders or pain, or to provide neuroprotection, or to induce diuresis, or to modulate the immune system, or for treatment of one or more of an affective disorders comprising depression or stress/anxiety; an addictive disorder; alcoholism, epilepsy; a cognition deficiency; schizophrenia; Alzheimer's disease; or pain.

Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

Abstract: A mobile media device user interface is described. In one or more implementations, output of a plurality of audio content is monitored by a mobile media device. Each of the audio content was received via a respective one of a plurality of broadcast channels by the mobile media device. A user interface is displayed on a display device of the mobile media device, the user interface describing each of the plurality of audio content and the respective broadcast channel from which the audio content was received.

Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

Abstract: A mobile media device user interface is described. In one or more implementations, output of a plurality of audio content is monitored by a mobile media device. Each of the audio content was received via a respective one of a plurality of broadcast channels by the mobile media device. A user interface is displayed on a display device of the mobile media device, the user interface describing each of the plurality of audio content and the respective broadcast channel from which the audio content was received.

Abstract: A method for improving performance of a pipelined microprocessor by utilizing pipeline virtual registers allows for either decreased register spillage or decreased area and power consumption of a microprocessor. The microprocessor takes advantage of register bypass logic to write short-lived values to virtual registers, which are discarded instead of being written to the register bank, thus reducing register pressure by avoiding short-lived values being written to the register bank.

Abstract: A system and method for configuring a configuring a register transfer level description from a programming language may utilize a configurable microprocessor core. A compiler may compile the programming language using performance statistics and user constraints. A template processor may translate the programming language into register transfer level description language using template files. Timing and area constraints may be used prior to output a gate level netlist ready to place on a microchip.

Abstract: A system and method for configuring a microprocessor core may allow a microprocessor core to be configurable. Configuration may be dynamic or automatic using an application program. Microprocessor memory, decoding units, arithmetic logic units, register banks, storage, register bypass units, and a user interface may be configured. The configuration may also be used to optimize an instruction set to run on the microprocessor core.

Abstract: Compounds of the following generic structure are provided: Such compounds activate a sphingosine-I-phosphate receptor of the subtype 1 (S1P1), and have utility in the treatment of malconditions mediated by S1P1 activation. More specifically, such compounds are beneficial in the treatment of, for example, multiple sclerosis, transplant rejection and/or adult respiratory syndrome.

Abstract: Compounds of the following generic structure are provided: Such compounds activate a sphingosine-I-phosphate receptor of the subtype 1 (S1P1), and have utility in the treatment of malconditions mediated by S1P1 activation. More specifically, such compounds are beneficial in the treatment of, for example, multiple sclerosis, transplant rejection and/or adult respiratory syndrome.

Abstract: Compounds of the following generic structure are provided: Such compounds activate a sphingosine-I-phosphate receptor of the subtype 1 (S1P1), and have utility in the treatment of malconditions mediated by S1P1 activation. More specifically, such compounds are beneficial in the treatment of, for example, multiple sclerosis, transplant rejection and/or adult respiratory syndrome.

Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.